# A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

> **NCT05198323** · PHASE2 · RECRUITING · sponsor: **Lumosa Therapeutics Co., Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** LT3001 Drug Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05198323
- **Lead sponsor:** Lumosa Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-11
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198323, "A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05198323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*